The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Is psilocybin heading to a cancer clinic near you?
Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research

Cancer Policy

OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds

Early-onset cancer bill introduced in Congress

NIH calls for comment on proposal to limit the number of RPGs per PI

Federal judge blocks Trump policy to charge $100,000 fee for H1-B visas

Cancer patients could be exempted from Medicaid work requirements if they prove they are “medically frail”

Richard Pazdur joins Friends board

Clinical Roundup

All-oral regimen of decitabine-cedazuridine + venetoclax yields 47% complete response rate, ASCERTAIN-V phase I/II clinical trial finds

Talvey + Darzalez Faspro shows significant survival gains in r/r MM, phase III MonumenTAL-3 study finds

Jaypirca + venetolax + rituximab reduced the risk of disease progression or death by 45% in r/r CLL/SLL, phase III BRUIN CLL-322 trial finds

Vispa-cel well-tolerated in second-line large B cell lymphoma, ANTLER phase I study finds

Antibody may improve treatment response in lung cancer, UTSW-led study finds

Alliance digital tool proves effective at keeping patients engaged in trials

In The Clinic
FreeTrials & Tribulations

Lessons from the AIDS Quilt: what the cancer world can learn from AIDS advocacy

Trials & Tribulations
Trials & Tribulations
Latest Issue
Read the latest issue
Read the latest issue
DOWNLOAD THE PDF
UPCOMING EVENTS
Jun 2026
25
MASCC/ISOO 2026 Annual Meeting
Sep 2026
18
NCCN 2026 Annual Congress: Hematologic Malignancies™️
Oct 2026
16
2026 ASCO Quality Care Symposium
29
5TH ANNUAL SYLVESTER CANCER SURVIVORSHIP SYMPOSIUM
View All Events

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account